respiratory syncytial virus, subgroup a, f protein subunit 847a stabilized in prefusion
SpainDrugs containing this active substance
-
It is a vaccine designed to prevent lung disease caused by respiratory syncytial virus (RSV). It is used to protect infants (from birth to 6 months) when administered to pregnant women, and also for individuals aged 18 years or older.
Form: powder and solvent for solution for injection
Active substance Dosage respiratory syncytial virus, subgroup a, f protein subunit 847a stabilized in prefusion 0,06 mg respiratory syncytial virus, subgroup b, f protein subunit 847b stabilized in prefusion 0,06 mg Manufacturer: Pfizer Europe Ma Eeig